{
    "doi": "https://doi.org/10.1182/blood.V112.11.4031.4031",
    "article_title": "Acute Pulmonary Hemorrhage in Patients with Acute Myeloid Leukemia (AML) during Remission Induction Chemotherapy ",
    "article_date": "November 16, 2008",
    "session_type": "Acute Myeloid Leukemia - Therapy, excluding Transplantation",
    "abstract_text": "Background: Acute pulmonary hemorrhage is an established complication during remission induction in patients with AML. Its pathogenesis is not well known. Injury to the alveolar capillary endothelium and release of inflammatory cytokines may play a role. The standard management is usually not effective. Aim: To analyze the course of patients with newly diagnosed AML who develop pulmonary hemorrhage during induction chemotherapy. Study Group: 1765 patient with AML received frontline therapy from 1998\u20132005. We analyzed 53 patients (3%) who were admitted to medical intensive care unit due to acute pulmonary hemorrhage. Results: The incidence of pulmonary hemorrhage was 3%. Outcome by patients characteristic was:  parameters . category . Total No. . Pulmonary Hemorrhage . (%) . P value . Age (years) >60\u2028 \u226460 998\u2028 767 32\u2028 21 3%\u2028 3% 0.569 Diagnosis M3\u2028 M4-M5\u2028 others 109\u2028 319\u2028 1337 812\u2028 33 7%\u2028 4%\u2028 2% 0.011 Platelet (\u00d710 9 /L) \u226520\u2028 <20 1475\u2028 290 43\u2028 10 3%\u2028 3% 0.624 WBC (\u00d710 9 /L) >10\u2028 \u226410 653\u2028 1112 32\u2028 21 5%\u2028 2% 0.000 Performance status 0\u20132\u2028 3\u20134 1662\u2028 103 44\u2028 9 3%\u2028 9% 0.000 Serum CR (mg/dl) 1.5 1622\u2028 140 46\u2028 7 3%\u2028 5% 0.150 HGB (g/dl) 8.0 872\u2028 893 32\u2028 21 4%\u2028 2% 0.105 Infection No\u2028 Yes 1218\u2028 494 32\u2028 21 3%\u2028 3% 0.089 parameters . category . Total No. . Pulmonary Hemorrhage . (%) . P value . Age (years) >60\u2028 \u226460 998\u2028 767 32\u2028 21 3%\u2028 3% 0.569 Diagnosis M3\u2028 M4-M5\u2028 others 109\u2028 319\u2028 1337 812\u2028 33 7%\u2028 4%\u2028 2% 0.011 Platelet (\u00d710 9 /L) \u226520\u2028 <20 1475\u2028 290 43\u2028 10 3%\u2028 3% 0.624 WBC (\u00d710 9 /L) >10\u2028 \u226410 653\u2028 1112 32\u2028 21 5%\u2028 2% 0.000 Performance status 0\u20132\u2028 3\u20134 1662\u2028 103 44\u2028 9 3%\u2028 9% 0.000 Serum CR (mg/dl) 1.5 1622\u2028 140 46\u2028 7 3%\u2028 5% 0.150 HGB (g/dl) 8.0 872\u2028 893 32\u2028 21 4%\u2028 2% 0.105 Infection No\u2028 Yes 1218\u2028 494 32\u2028 21 3%\u2028 3% 0.089 View Large The predictive factors for pulmonary hemorrhage were: leukemia morphology (M3, M4\u20135), performance status and WBC count. The 8week survival of patients who develop pulmonary hemorrhage was 32%, (median survival days from pulmonary hemorrhage to death is 16 days). Conclusion: pulmonary hemorrhage is a serious complication of induction therapy in AML. Modalities that reduce its incidence are needed.",
    "topics": [
        "chemotherapy regimen",
        "leukemia, myelocytic, acute",
        "pulmonary alveolar hemorrhage",
        "remission induction",
        "chemotherapy, neoadjuvant",
        "cytokine",
        "hemoglobin",
        "infections",
        "leukemia",
        "neoadjuvant therapy"
    ],
    "author_names": [
        "Ali M Alameri, MD",
        "Charles Asa Koller",
        "Sherry Pierce",
        "Gloria Mattiuzzi, MD"
    ],
    "author_dict_list": [
        {
            "author_name": "Ali M Alameri, MD",
            "author_affiliations": [
                "Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Charles Asa Koller",
            "author_affiliations": [
                "Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Sherry Pierce",
            "author_affiliations": [
                "M.D. Anderson Cancer Center, Houston, TX, USA"
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Gloria Mattiuzzi, MD",
            "author_affiliations": [
                "Leukemia, UT MD Anderson Cancer Center, Houston, TX, USA"
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-08T06:39:52",
    "is_scraped": "1"
}